J Diabetes Investig 2018; 9: 1075--1083

Introduction {#jdi12824-sec-0005}
============

Type A insulin resistance syndrome is on the right side (from severe to mild) of the congenital severe insulin resistance syndrome spectrum due to mutations in the insulin receptor (*INSR)* gene. On the left side are Donohue syndrome and Rabson--Mendenhall syndrome caused by homozygous mutation or compound heterozygous mutations involving the α subunit of the *INSR* gene, and patients usually do not survive to adulthood. In contrast, type A insulin resistance syndrome is relatively mild. It is usually diagnosed in lean female patients complaining of hirsutism, oligomenorrhea, acne and acanthosis nigricans during puberty, which results from hyperandrogenism due to severe insulin resistance and polycystic ovaries. Genetic screening usually identifies a single heterozygous mutation involving the tyrosine kinase domain in the β subunit of the *INSR* gene.[1](#jdi12824-bib-0001){ref-type="ref"} The mutations in this area cause insulin resistance in a dominant‐negative fashion.[2](#jdi12824-bib-0002){ref-type="ref"}, [3](#jdi12824-bib-0003){ref-type="ref"}, [4](#jdi12824-bib-0004){ref-type="ref"} In heterozygous mutation carriers, only the symmetrical wild‐type receptor (a~2~\[β~wt~\]~2~) is active as a tyrosine kinase, whereas the hybrid α~2~β~wt~β~mut~ and the symmetrical a~2~(β~mut~)~2~ receptors are inactive.[5](#jdi12824-bib-0005){ref-type="ref"} Thus, the autophosphorylation at multiple sites in the tyrosine kinase domain in response to insulin binding is blocked in the defective receptor, so thus the subsequent signaling transduction pathway that induced GLUT4 translocation to the membrane, as well as the synthesis of glycogen and lipid.[1](#jdi12824-bib-0001){ref-type="ref"}

There are not many reports in the literature about the treatment of type A insulin resistance syndrome. Meformin and thiazolidinediones, two traditional insulin sensitizers, were the initial choices of medication in sporadic case reports. Glimepiride, a potent insulin secretogogoue to treat type 2 diabetes, has been shown to have unique insulin mimetic/sensitizing effects by acting on the caveolin/detergent‐insoluble glycolipid‐ enriched rafts (DIG) areas, causing the activation of non‐receptor tyrosine kinase (non‐RTK), such as pp59^Lyn^, to phosphorylates insulin receptor substrate proteins, which are downstream of the insulin receptor, initiating the metabolic insulin‐mimetic signaling to the lipid and glycogen synthesis pathways, and the GLUT4 translocation.[6](#jdi12824-bib-0006){ref-type="ref"} A recent study[7](#jdi12824-bib-0007){ref-type="ref"} also showed that glimepiride had peroxisome proliferator‐activated receptor‐γ (PPARγ) agonist activity, whose potencies were 16--25% of the maximum level achieved by pioglitazone.

In the present study, we aimed to investigate the efficacy of glimepiride in a patient with type A insulin resistance syndrome due to a novel heterozygous missense mutation of Ile1143Phe in exon 19 of the *INSR* gene. Hyperinsulinemic euglycemic clamp was used to evaluate the change in insulin sensitivity before and after the treatment.

Methods {#jdi12824-sec-0006}
=======

Case report {#jdi12824-sec-0007}
-----------

The participant was a 15‐year‐old girl who was born at full‐term from non‐consanguineous parents. Her birthweight was 2.2 kg (P3). She was found to be hirsute since the age of 5 years. Secondary sex characters and accelerated growth occurred from the age of 13 years, but no menarche occurred. Her body mass index (BMI) was 18.4 kg/m^2^. Plasma glucose during a 5‐h oral glucose tolerance test was 7.2, 17.1, 18.6, 14.2, 12.9 and 6.8 mmol/L at 0, 1‐h, 2‐h, 3‐h, 4‐h and 5‐h time‐points. Simultaneous measurements of serum insulin were 96.1, 256.8, \>300, \>300, \>300 and 258.9 μU/mL. The patient\'s glycated hemoglobin (HbA1c) was 6.8%. Ultrasound showed polycystic ovaries. Her serum testosterone was mildly elevated to 0.97 ng/mL (normal range 0.1--0.75 ng/mL). Diagnosis of type A insulin resistance syndrome was made, and the patient was prescribed pioglitazone 15 mg/day for 6 consecutive months, but no improvement in plasma glucose nor serum insulin was evident. Serum fasting insulin was 80.7 μU/mL, and HbA1c was 7.0% after the suspension of pioglitazone. No menstrual onset was recorded during or after the treatment.

Genetic analysis {#jdi12824-sec-0008}
----------------

Peripheral blood (5 mL) of the patient was sent to BGI Diagnosis Co., Shenzhen, Guangdong province, China (certified with ISO 15189), for next generation sequencing, targeting a panel of 11 genes (*INSR*,*ABCC8*,*KCNJ11*,*GCK*,*HADH*,*GLUD1*,*HNF4A*,*HNF1A*,*UCP2*,*FOXA2, SLC16A1*) known to be associated with congenital hyperinsulinism.[8](#jdi12824-bib-0008){ref-type="ref"} Genomic DNA was extracted using QIAamp DNA Blood Midi Kit (Qiagen, Hilden, Germany), then sheared by Covaris LE220 (Woburn, MA, USA) to generate a paired‐end library (200--250 bp). The library was enriched by array hybridization, followed by elution and post‐capture amplification. The products were subjected to Agilent 2100 Bioanalyzer (Agilent, CA, USA) and ABI StepOne (Thermo Fisher Scientific, Waltham, MA, USA) to estimate the magnitude of enrichment. After quality control, captured library sequencing was carried out on Illumina HiSeq2500 Analyzers (Illumina, San Diego, CA, USA) for 90 cycles per read to generate paired‐end reads. Image analysis, error estimation and base calling were carried out using Illumina Pipeline software (version 1.3.4; Illumina, San Diego, CA, USA) to generate raw data.

To detect potential variants, bioinformatics processing and data analysis was carried out. Filtering criteria to generate "clean reads" was used as reported in the literature.[9](#jdi12824-bib-0009){ref-type="ref"} The "clean reads" (with a length of 90 bp) derived from targeted sequencing and filtering were then aligned to the human genome reference (hg19) using the Burrows Wheeler Aligner Multi‐Vision software package (available from: <http://maq.sourceforge.net>). After alignment, the output files were used to carry out sequencing coverage and in‐depth analysis of the target region, single‐ nucleotide variants and insertion/deletion calling.[10](#jdi12824-bib-0010){ref-type="ref"}

SOAPsnp software (available from <http://soap.genomics.org.cn> under GPL license) and Samtools (available from: <http://samtools.sourceforge.net>) was used to detect single‐ nucleotide variants and insertion/deletions. All single‐nucleotide variants and insertion/deletions were filtered and estimated through multiple databases, including NCBI dbSNP, HapMap, 1,000 human genome dataset and database of 100 Chinese healthy adults.[11](#jdi12824-bib-0011){ref-type="ref"}

To predict the effect of missense variants, dbNSFP was used containing well established *in silico* prediction programs (Polyphen2, MutationTaster, Scale‐Invariant Feature Transform, LRT and PhyloP). Pathogenic variants were assessed under the protocol issued by the American College of Medical Genetics.[12](#jdi12824-bib-0012){ref-type="ref"} The Human Gene Mutation Database was used to screen mutations reported in published studies. All mutations and potential pathogenic variants were validated using conventional Sanger sequencing methods.

Hyperinsulinemic euglycemic clamp study {#jdi12824-sec-0009}
---------------------------------------

The hyperinsulinemic euglycemic clamp was carried out before and after the treatment with glimepiride. After a 12‐h overnight fast, an intravenous cannula was inserted into the antecubital vein of both arms. Blood from the right was arterialized by placing the arm continuously in an electric warmer set at approximately 50°C, and sampled for plasma glucose and serum insulin. First‐phase insulin secretion was determined by an intravenous glucose tolerance test before the initiation of insulin infusion. Serum insulin concentration was sampled at 0, 1, 2, 4, 6 and 10 min after intravenous injection of 50% glucose 50 mL within 1 min. Then a primed (3 mU/kg/min) and continuous (1 mU/kg/min) infusion of regular insulin was started, and plasma glucose was measured with a glucose analyzer (Beckman Instruments, Brea, CA, USA) at 5‐min intervals throughout the clamp study. A variable infusion of 20% dextrose was used to maintain euglycemia (4.4--5.0 mmol/L). Steady‐state was achieved approximately 120 min after insulin infusion. Whole‐body glucose uptake was estimated as the metabolic rate (M value), defined as the infusion rate of exogenous glucose, corrected for urinary glucose losses and the glucose space correction. The clamp data were compared with those of six normal glucose tolerance (NGT) young (aged 22.8 ± 0.4 years) women who had matched BMI (18.8 ± 1.3 kg/m^2^) and no familial history of diabetes, as well as 13 newly diagnosed patients with type 2 diabetes and 17 individuals with impaired glucose tolerance (IGT).

Treatment protocol with glimepiride {#jdi12824-sec-0010}
-----------------------------------

Glimepiride was started the next day after hyperinsulinemic euglycemic clamp from a small dose (1 mg/d), and titrated every 2 weeks by 1 mg each time, until 6 mg/day was achieved as the maximum, and maintained the dosage thereafter. The whole treatment period lasted for a total of 6 months. Self‐monitored blood glucose during fasting, 2 h after each meal, and that before dinner and bedtime was recorded on 1 day every week. Hypoglycemia and other adverse events were carefully monitored. Oral glucose tolerance tests were carried out during the first 3 months of the titration for the measurement of plasma glucose and serum insulin concentration. One week after the suspension of glimepiride, hyperinsulinemic euglycemic clamp study was repeated.

The study was approved by the Medical Research and Ethics Committee of the First Affiliated Hospital of Sun Yat‐sen University. Written informed consent was obtained from all the participants.

Results {#jdi12824-sec-0011}
=======

Novel heterozygous missense mutation (Ile1143Phe) identified in the *INSR* gene {#jdi12824-sec-0012}
-------------------------------------------------------------------------------

There were in total 17 variants identified in either the exons or the flanking intron areas in eight out of the 11 screened genes, as listed in Table [1](#jdi12824-tbl-0001){ref-type="table"}. Most of the variants were documented in the 1,000 Genome project database with varying frequencies, and showed benign changes or polymorphisms. Four heterozygous mutations occurred in the *INSR* gene, two of which were silent mutations in the coding region (Ala550Ala in exon 8 and His1085His in exon 17). A novel heterozygous missense mutation at exon 19 (c.3427A\>T) in the catalytic group of the tyrosine kinase domain in the β subunit of the *INSR* gene was identified, causing an amino acid replacement of phenylalanine for isoleucine, which has never been reported in the literature (Figure [1](#jdi12824-fig-0001){ref-type="fig"}a). Prediction of the impact of the altered amino acid using Polyphen2 and MutationTaster programs and so on showed that the missense mutation was deleterious. The isoleucine 1,143 is exquisitely conserved among orthologs in different species, thus the mutation is probably pathogenic (Figure [1](#jdi12824-fig-0001){ref-type="fig"}b). Another novel polymorphism (c.653‐5\_‐4 delTC) in intron 2 was also identified, the significance of which was illusive.

###### 

Variants identified in the coding regions as well as the flanking intron regions in genes related to severe insulin resistance

  No.   Gene        Transcript                     Nucleotide change   Amino acid change   Chromosome           Exon/intron   Heterozygosity   Frequency
  ----- ----------- ------------------------------ ------------------- ------------------- -------------------- ------------- ---------------- -----------
  1     *SLC16A1*   [NM_003051](NM_003051)         c.1470T\>A          p.Asp490Glu         chr1:113456546       Exon 5        Hom              0.4533
  2     *GLUD1*     [NM_005271](NM_005271)         c.942A\>G           p.Leu314Leu         chr10:88820789       Exon 7        Hom              0.1062
  3     *KCNJ11*    [NM_001166290](NM_001166290)   c.748G\>A           p.Val250Ile         chr11:17408630       Exon 2        Hom              0.5321
  4     *KCNJ11*    [NM_001166290](NM_001166290)   c.309C\>T           p.Ala103Ala         chr11:17409069       Exon 2        Het              0.3544
  5     *ABCC8*     [NM_000352](NM_000352)         c.4105G\>T          p.Ala1369Ser        chr11:17418477       Exon 33       Hom              0.5256
  6     *ABCC8*     [NM_000352](NM_000352)         c.3819G\>A          p.Arg1273Arg        chr11:17419279       Exon 31       Het              0.4002
  7     *ABCC8*     [NM_000352](NM_000352)         c.1947G\>A          p.Lys649Lys         chr11:17449929       Exon 14       Het              0.2729
  8     *ABCC8*     [NM_000352](NM_000352)         c.207T\>C           p.Pro69Pro          chr11:17496516       Exon 2        Het              0.5256
  9     *UCP2*      [NM_003355](NM_003355)         c.164C\>T           p.Ala55Val          chr11:73689104       Exon 4        Het              0.5009
  10    *INSR*      [NM_000208](NM_000208)         c.3427A\>T          p.Ile1143Phe        chr19:7122727        Exon 19       Het              0
  11    *INSR*      [NM_000208](NM_000208)         c.3255C\>T          p.His1085His        chr19:7125297        Exon 17       Het              0.3782
  12    *INSR*      [NM_000208](NM_000208)         c.1650G\>A          p.Ala550Ala         chr19:7166376        Exon 8        Het              0.3416
  13    *FOXA2*     [NM_153675](NM_153675)         c.1188A\>G          p.Gln396Gln         chr20:22562674       Exon 3        Hom              0.881
  14    *GCK*       [NM_000162](NM_000162)         c.1253 + 8C\>T      --                  chr7:44185088        Intron 9      Het              0.3791
  15    *ABCC8*     [NM_000352](NM_000352)         c.2117‐3C\>T        --                  chr11:17448704       Intron 15     Het              0.4451
  16    *INSR*      [NM_000208](NM_000208)         c.653‐5\_‐4 delTC   --                  chr19:7184652..718   Intron 2      Het              0
  17    *HNF4A*     [NM_175914](NM_175914)         c.50‐5C\>T          --                  chr20:43034693       Intron 1      Het              0.3095

Het, heterozygous; Hom, homozygous.
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![(a) Sequencing of the insulin receptor (*INSR*) gene in the patient and wild‐type control. The arrow shows the nucleotide position at 3,427, where the original A was replaced by T, resulting in a heterozygous missense mutation of phenylalanine for isoleucine at codon 1,143. (b) Alignment of the insulin receptor amino acid sequences from different species. The isoleucine 1,143 residue is highlighted in yellow for each sequence.](JDI-9-1075-g001){#jdi12824-fig-0001}

Direct sequencing of the *INSR* gene was also carried out in both parents and the patient\'s younger brother, none of who were hyperinsulinemic (Table[2](#jdi12824-tbl-0002){ref-type="table"}). The Ile1143Phe missense mutation was not identified in any of them. Microsatellite analysis was suggested to confirm the family relationship, but rejected by the parents. Thus, it was not certain whether the mutation had arisen *de novo*. Genetic screening was also declined outside of the family.

###### 

Plasma glucose and serum Insulin levels in family members

                          Father   Mother   Brother
  ----------------------- -------- -------- ---------
  Age (years)             48       48       13
  BMI (kg/m^2^)           24.6     18.2     18.9
  HbA1c (%)               6.6      5.3      4.8
  OGTT glucose (mmol/L)                     
  0 min                   8.4      5.3      5.2
  30 min                  15.0     8.4      11.0
  120 min                 12.2     9.1      7.2
  OGTT insulin (μU/mL)                      
  0 min                   8.5      1.5      2.6
  30 min                  51.8     21.1     64.3
  120 min                 64.4     64.3     51.7

BMI, body mass index; Hba1c, glycated hemoglobin; OGTT, oral glucose tolerance test.

John Wiley & Sons, Ltd

Clinical characteristics of the patient in comparison with NGT, IGT and type 2 diabetes controls {#jdi12824-sec-0013}
------------------------------------------------------------------------------------------------

The anthropometric values, glucose and insulin concentration during a 75‐g oral glucose tolerance test, lipid profiles and M value during the hyperinsulinemic euglycemic clamp of the patient was compared with NGT and glucose intolerant controls (Table [3](#jdi12824-tbl-0003){ref-type="table"}). The values of the patient that were out of the 95% confidence intervals of the control groups were denoted. As indicated, the patient had much lower percentage of body fat as compared with NGT participants with similar BMI, waist circumference and waist‐to‐hip ratio. The HbA1c of the patient was comparable with that of the individuals with diabetes, whereas serum insulin levels were significantly higher. However, serum lipid profiles of the patient were not deranged in contrast to those of the IGT and diabetes controls. The M value was the highest in the NGT participants, and decreased with the impairment of glucose tolerance. The M value of the patient was comparable with that of the individuals with IGT and diabetes before the treatments.

###### 

Clinical characteristics of the patient and that of the control individuals with normal glucose tolerance, impaired glucose tolerance and type 2 diabetes

                          Patient Ile1143Phe   NGT control                                            IGT                                                     T2DM
  ----------------------- -------------------- ------------------------------------------------------ ------------------------------------------------------- ----------------------------------------------------------
  *n*                     --                   6                                                      17                                                      13
  Age (years)             15                   22.8 ± 0.4[\*](#jdi12824-note-0003){ref-type="fn"}     53.1 ± 6.6[\*\*](#jdi12824-note-0003){ref-type="fn"}    50.9 ± 7.3 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  Sex (female/male)       Female               Female                                                 14/3                                                    7/6
  BMI (kg/m^2^)           18.9                 18.8 ± 1.3                                             26.2 ± 2.7[\*\*](#jdi12824-note-0003){ref-type="fn"}    26.4 ± 2.8 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  Waist (cm)              62.0                 65.0 ± 4.9                                             84.8 ± 6.7[\*\*](#jdi12824-note-0003){ref-type="fn"}    89.8 ± 6.9 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  Waist/hip ratio         0.72                 0.72 ± 0.05                                            0.88 ± 0.06[\*\*](#jdi12824-note-0003){ref-type="fn"}   0.94 ± 0.07 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  Fat%                    10.9                 20.3 ± 5.6[\*](#jdi12824-note-0003){ref-type="fn"}     31.7 ± 6.3[\*\*](#jdi12824-note-0003){ref-type="fn"}    30.6 ± 9.5 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  OGTT glucose (mmol/L)                                                                                                                                       
  0 min                   6.7                  4.8 ± 0.3[\*](#jdi12824-note-0003){ref-type="fn"}      5.1 ± 0.4[\*\*](#jdi12824-note-0003){ref-type="fn"}     7.5 ± 1.6
  30 min                  12.8                 7.4 ± 0.8[\*](#jdi12824-note-0003){ref-type="fn"}      10.2 ± 1.7[\*\*](#jdi12824-note-0003){ref-type="fn"}    13.6 ± 2.2
  120 min                 17.3                 5.0 ± 1.3[\*](#jdi12824-note-0003){ref-type="fn"}      8.9 ± 1.0[\*\*](#jdi12824-note-0003){ref-type="fn"}     15.7 ± 2.9
  OGTT insulin (μU/mL)                                                                                                                                        
  0 min                   80.7                 4.9 ± 2.4[\*](#jdi12824-note-0003){ref-type="fn"}      8.4 ± 6.4[\*\*](#jdi12824-note-0003){ref-type="fn"}     11.7 ± 5.8 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  30 min                  137.5                76.0 ± 91.8[\*](#jdi12824-note-0003){ref-type="fn"}    93.4 ± 44.4[\*\*](#jdi12824-note-0003){ref-type="fn"}   139.0 ± 74.8
  120 min                 \>300                30.3 ± 17.0[\*](#jdi12824-note-0003){ref-type="fn"}    87.9 ± 43.5[\*\*](#jdi12824-note-0003){ref-type="fn"}   99.1 ± 33.4 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  HbA1c (%)               7.0                  5.3 ± 0.2[\*](#jdi12824-note-0003){ref-type="fn"}      6.0 ± 0.4[\*\*](#jdi12824-note-0003){ref-type="fn"}     7.3 ± 1.2
  Cholesterol (mmol/L)    4.8                  --                                                     6.0 ± 1.0[\*\*](#jdi12824-note-0003){ref-type="fn"}     5.4 ± 1.1 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  Triglyceride (mmol/L)   1.6                  --                                                     1.8 ± 0.7                                               2.5 ± 1.2 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  LDL‐c (mmol/L)          2.9                  --                                                     4.3 ± 1.0[\*\*](#jdi12824-note-0003){ref-type="fn"}     3.8 ± 1.0 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  HDL‐c (mmol/L)          1.3                  --                                                     1.2 ± 0.3                                               1.1 ± 0.2 [\*\*\*](#jdi12824-note-0003){ref-type="fn"}
  M value (mg/kg/min)                                                                                                                                         
  Clamp 1                 5.25                 10.69 ± 5.25[\*](#jdi12824-note-0003){ref-type="fn"}   5.91 ± 1.95                                             4.83 ± 2.81
  Clamp 2                 2.90                 10.69 ± 5.25[\*](#jdi12824-note-0003){ref-type="fn"}   5.91 ± 1.95[\*\*](#jdi12824-note-0003){ref-type="fn"}   4.83 ± 2.81[\*\*\*](#jdi12824-note-0003){ref-type="fn"}

\*Patient\'s value outside the range of the 95% confidence interval of the individuals with normal glucose tolerance (NGT). \*\*Patient\'s value outside the range of the 95% confidence interval of the individuals with impaired glucose tolerance (IGT). \*\*\*Patient\'s value outside the range of the 95% confidence interval of the type 2 diabetes patients. BMI, body mass index; Hba1c, glycated hemoglobin; HDL‐c, high‐density lipoprotein cholesterol; LDL‐c, low‐density lipoprotein cholesterol; OGTT, oral glucose tolerance test.
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Intravenous glucose tolerance tests in the NGT participants and patients with heterozygous *INSR* gene mutations (Ile1143Phe *vs* Arg1174Trp) {#jdi12824-sec-0014}
---------------------------------------------------------------------------------------------------------------------------------------------

First‐phase insulin secretion was evaluated in the patient and six individuals with NGT using an intravenous glucose tolerance test before the initiation of insulin infusion during the hyperinsulinemic euglycemic clamp. The acute insulin secretion profile was also compared with another patient diagnosed with type A insulin resistance syndrome with a heterozygous missense mutation (Arg1174Trp) in exon 20 of the *INSR* gene, as we had described previously, and followed for 14 years up till now.[13](#jdi12824-bib-0013){ref-type="ref"}, [14](#jdi12824-bib-0014){ref-type="ref"}

Briefly, the patient with the Arg1174Trp mutation was aged 16 years at her first visit. She was slim (BMI 17.8 kg/m^2^), and complained of intermittent hunger, fatigue and dizziness before lunch or bedtime. She also presented with hirsutism, oligomenorrhea and polycystic ovaries. She was found to have hyperinsulinemic hypoglycemia, severe insulin resistance and diabetes. No pharmaceutical intervention was given to the patient other than yearly follow up on her glucose, insulin profiles and menstruation. With the passage of her puberty, insulin hypersecretion, glucose deterioration and hypoglycemic symptoms tended to relieve. Her menstruation period was somehow regular without hormonal replacement therapy. Her HbA1c in this year\'s follow up (at the age of 30 years) was 5.3%, and her fasting insulin concentration dropped to 14.3 μU/mL, much lower than 210 μU/mL when she was aged 16 years.

As shown in Figure [2](#jdi12824-fig-0002){ref-type="fig"}a, the fasting serum insulin of the individuals with NGT was relatively low (4.93 ± 2.02 μU/mL), then gained an averaged 17‐fold increment at 2 min after glucose injection (85.0 ± 60.5 μU/mL). In contrast, the patient with the Ile1143Phe mutation had severe fasting hyperinsulinemia, but lost first‐phase insulin secretion, which was similar to that seen in patients with type 2 diabetes. However, the patient with the Arg1174Trp mutation maintained a sharp peak of insulin secretion 17‐fold of the fasting state (240.6 *vs* 14.3 μU/mL), and the increment fold was comparable with the individuals with NGT.

![(a) Comparison of first‐phase insulin secretion induced by intravenous glucose tolerance test in the six individuals with normal glucose tolerance (NGT; circle) and that of the patient with the Ile1143Phe mutation (inverse triangle) and patient with the Arg1174Trp mutation (triangle). (b) Self‐monitored blood glucose in the patient carrying the Ile1143Phe mutation during the treatment with glimepiride by different dosages.](JDI-9-1075-g002){#jdi12824-fig-0002}

Efficacy and safety of glimepiride treatment in the patient with the Ile1143Phe mutation {#jdi12824-sec-0015}
----------------------------------------------------------------------------------------

Figure [2](#jdi12824-fig-0002){ref-type="fig"}b shows the self‐monitored blood glucose of the patient during the titration of glimepiride from 1 mg/day to 6 mg/day. There was no significant difference between glucose concentration measured at each time‐point among different glimepiride dosages. When the maximal dosage (6 mg/day) was achieved and maintained for a total of 14 weeks, there was no significant difference between glucose concentrations measured at each time‐point between each week. Oral glucose tolerance test during the titration period showed that there were few changes in plasma glucose and serum insulin levels (Table [4](#jdi12824-tbl-0004){ref-type="table"}). HbA1c at the end of the treatment was 6.2%, decreased by 0.8%, as compared with that (7%) before the treatment. However, hyperinsulinemic euglycemic clamp study showed that the M value further decreased to 2.90 mg/kg/min, indicating increased insulin resistance after the treatment.

###### 

Oral glucose tolerance test during glimepiride treatment

  Glimepiride dosage   Plasma glucose (mmol/L)   Serum insulin (μU/mL)                           
  -------------------- ------------------------- ----------------------- ------ ------- -------- --------
  2 mg/day             5.8                       12.4                    16.8   75.69   154.12   818.19
  4 mg/day             5.1                       11.8                    17.3   70.10   192.03   858.40
  6 mg/day             5.7                       10.9                    15.0   68.02   135.22   625.75

John Wiley & Sons, Ltd

Mild‐to‐moderate hypoglycemic symptoms (hunger and trembling) occurred several times (a total of 5 times in 6 months) during the treatment, especially when meals were delayed. The nadir value was 2.2 mol/L, and occurred just once before bedtime at the dosage of 6 mg/day. The symptoms were relieved rapidly with food ingestion. The patient gained 1 kg during the whole treatment period. No other adverse event was recorded during or after the treatment.

Discussion {#jdi12824-sec-0016}
==========

In the present study, we reported a 15‐year‐old girl diagnosed with type A insulin resistance syndrome carrying a novel heterozygous missense mutation of Ile1143Phe in exon 19 of the *INSR* gene. Even though we did not carry out detailed experiments to check for the functional consequence of the mutation, multiple well‐established *in silico* prediction programs showed that the mutation is hazardous. Furthermore, the phenotype of the patient (lean female, small for gestational age, hirsutism, amenorrhea, polycystic ovaries, severe hyperinsulinemia) matched the common genotypes of the mutation occurring in the tyrosine kinase domain of the *INSR* gene. Thus, we believe that the mutation is pathogenic and is responsible for the severe insulin resistance in this patient. We treated the patient with glimepiride for 6 months. Even though her HbA1c decreased by 0.8% after the treatment, her serum insulin during oral glucose tolerance test, or insulin resistance as evaluated by hyperinsulinemic euglycemic clamp showed that glimepiride did not improve insulin sensitivity in this patient.

Glimepiride is a potent insulin secretogogoue, the efficacy and safety of which has long been validated in clinical practice for the treatment of type 2 diabetes. Thus, it might be disputable to use glimepiride in patients with severe hyperinsulinemia. Our assumption was based on the two unique insulin‐sensitizing aspects of glimepiride. First, Müller *et al*.[6](#jdi12824-bib-0006){ref-type="ref"} proposed the working model for direct insulin mimetic and sensitizing signaling of glimepiride based on rigorous *in vitro* experiments. Glimepiride partitions directly into the caveolin/DIG areas of the adipocyte or myocyte plasma membranes in a non‐saturable and time‐dependent fashion, thereby causing redistribution of specific DIG/caveolin/non‐RTK components. An acylated non‐RTK, such as pp59^Lyn^, is thus freed from inhibition, and dissociates from caveolin and migrates into the non‐DIG areas of the plasma membrane. The activated non‐RTK (pp59^Lyn^) then bypasses the insulin receptor and phosphorylates insulin receptor substrate proteins directly, and initiates downstream signaling of lipid and glycogen synthesis, as well as GLUT4 translocation through the phosphatidylinositol‐4,5‐bisphosphate 3‐kinase pathway.[15](#jdi12824-bib-0015){ref-type="ref"}, [16](#jdi12824-bib-0016){ref-type="ref"} In contrast, Fukuen *et al*.[7](#jdi12824-bib-0007){ref-type="ref"} found that glimepiride specifically induced the transcriptional activity of PPARγ in luciferase reporter assays. It directly bound to PPARγ in a manner competitive with rosiglitazone.[17](#jdi12824-bib-0017){ref-type="ref"} In 3T3‐L1 adipocytes, glimepiride stimulated the transcriptional activity of the gene promoter containing PPAR‐responsive element and altered messenger ribonucleic acid levels of PPARγ target genes including aP2, leptin and adiponectin. The data strongly suggested that glimepiride had PPARγ agonist activity, whose potency was approximately 16--25% of the maximum level achieved by pioglitazone.[7](#jdi12824-bib-0007){ref-type="ref"} All these data suggested that glimepiride improves insulin sensitivity through multiple signaling pathways. Unfortunately, we could not validate its insulin‐sensitizing effect in this patient. Adipocyte membrane is the major site that glimepiride acts on. As the patient had relatively less fatty mass, we could not exclude it to be partially responsible for the null effect of glimepiride. In contrast, the proportion of glimepriride under routine treatment concentration that initiates the activation of the DIGs--caveolin--pp59Lyn pathway is elusive, thus it is not clear whether longer treatment duration or a higher dose of glimepiride could improve insulin sensitivity. Further study of constructing cell lines or animal models with the corresponding defective insulin receptor, followed by experiments on the optimal concentration of the insulin‐sensitizing effect of glimepiride is warranted.

Type A insulin resistance syndrome is usually diagnosed in lean adolescent girls complaining of hirsutism, oligomenorrhea, acne and acanthosis nigricans, which results from hyperandrogenism due to severe insulin resistance and polycystic ovaries. However, the phenotypes usually vary in patients with different gene mutations; for example, the degree of hyperinsulinemia. The fasting and post‐load serum insulin level in the patient with the Arg1174Trp mutation (at the age of 16 years) was 3--4‐fold higher than the patient with the Ile1143Phe mutation in the present study. Hyperinsulinemic hypoglycemia was the major clinical feature in the former, but absent in the latter. The first‐phase insulin secretion remained intact in the patient with the Arg1174Trp mutation during the 14 years of follow up. However, the patient with the Ile1143Phe mutation lost the acute insulin response to glucose injection at the early stage of diagnosis, and the impact on glucose metabolism in the future remains to be determined. Therefore, we could infer from this observation that the efficacies of insulin sensitizers, besides glimepiride, might also vary among different *INSR* gene mutation carriers. Thus, the null effect in the present case is not necessarily the same in other patients with type A insulin resistance syndrome.

Treatment of severe insulin resistance syndrome due to insulin receptoropathy is usually empirical and lacks evidence.[18](#jdi12824-bib-0018){ref-type="ref"} Metformin and thiazolidinediones were used even in infants with Donohue syndrome and Rabson--Mendenhall syndrome in addition to a huge amount of daily insulin and rhIGF‐1, but were not consistently effective.[19](#jdi12824-bib-0019){ref-type="ref"}, [20](#jdi12824-bib-0020){ref-type="ref"} Treatment with leptin was reported in multiple cases of Rabson--Mendenhall syndrome.[21](#jdi12824-bib-0021){ref-type="ref"}, [22](#jdi12824-bib-0022){ref-type="ref"} Brown *et al* [22](#jdi12824-bib-0022){ref-type="ref"} studied the effect of metreleptin in five patients for \>12 months, two of which were treated for 10 years. HbA1c declined with each cycle of metreleptin and rose with each withdrawal. Glycemic improvement in these patients was partly explained by weight loss associated with the treatment.[22](#jdi12824-bib-0022){ref-type="ref"} Acarbose was recommended in patients with type A insulin resistance syndrome who showed postprandial hyperglycemia and delayed hypoglycemia.[18](#jdi12824-bib-0018){ref-type="ref"} The efficacies of thiazolidinediones on type A insulin resistance syndrome varied. Hattori *et al*.[23](#jdi12824-bib-0023){ref-type="ref"} reported a female patient with heterozygous deletion mutation of Leu1026Del at exon 17 in the *INSR* gene, and was treated with pioglitazone for 10 months. Serum insulin, glucose levels and hyperandrogenism were ameliorated, and the patient resumed menstruation 2 months after the treatment.[23](#jdi12824-bib-0023){ref-type="ref"} In contrast, Vestergaard *et al*.[24](#jdi12824-bib-0024){ref-type="ref"} reported two brothers with biallelic deletion mutation at exon 17 of the *INSR* gene treated with rosiglitazone for 180 days. No improvement in plasma glucose, serum insulin and lipid profiles were evident.[24](#jdi12824-bib-0024){ref-type="ref"} In the present study, the patient with the Ile1143Phe mutation was treated with pioglitazone 15 mg/day for 6 months before glimepiride treatment, but this did not prove effective. Thus, the efficacies of thiazolidnediones in the treatment of type A insulin resistance syndrome remained to be determined. In contrast, the patient with the Arg1174Trp mutation did not receive any insulin‐sensitizing agent during the 14 years of follow up. However, hyperinsulinemic hypoglycemia and menstruation problems were somehow relieved with the passage of her puberty, and no diabetic microvascular or macrovascular complications were evident. Type A insulin resistance syndrome is relatively rare, and the correlation between genotype and phenotype varies.[25](#jdi12824-bib-0025){ref-type="ref"} There are not enough large‐scale, long‐term, follow‐up studies focusing on the treatment and prognosis in the literature to guide our treatment choices. There is a pressing need to assemble genotype and phenotype data of type A insulin resistance syndrome worldwide to optimize treatment algorithms.

There were some limitations to the present study. For example, we identified a novel missense mutation (Ile1143Phe) in the *INSR* gene. We did not carry out detailed experiments on the alteration of insulin receptor expression, insulin binding or autophosphorylation capacity of the tyrosine kinase domain. We assumed the mutation was responsible based on the fact that the phenotype of the patient matched the common genotypes of the mutation occurring in the tyrosine kinase domain of the *INSR* gene. Furthermore, the Ile1143 amino acid is highly conserved in multiple species. Replacement with a phenylalanine at this site is probably hazardous. In addition, multiple powerful programs, each with \>80% accuracy, unanimously predicted that the mutation is deleterious. Thus, there is still some strength for the assumption that the mutation is responsible for severe insulin resistance in this patient. In contrast, we did not examine the changes in the activity of the post‐insulin receptor signaling pathway, nor did we check for its PPARγ agonist activity before and after the treatment; therefore, we could not possibly explain the null effect of glimepiride in the study. Finally, expanding investigation of the genetic background and the associated phenotype outside the family was declined. Thus, analysis of the linkage and segregation of the mutation was not possible.

In summary, we reported a female patient with type A insulin resistance syndrome carrying a novel heterozygous missense mutation of Ile1143Phe in exon 19 of the *INSR* gene. Treatment with glimepiride for 6 months did not improve insulin sensitivity. Genotype and phenotype correlation varies in type A insulin resistance syndrome. Large‐scale, long‐term, follow‐up studies assembled worldwide are required to optimize treatment algorithms and prognosis.
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